Results 261 to 270 of about 160,542 (279)

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Annals of Oncology, 2021
Brett G M Hughes
exaly  

Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review

International Immunopharmacology, 2021
Dun-Chang Mo, Peng-Hui Luo, Jian-Feng Huang   +2 more
exaly  

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

European Journal of Cancer, 2020
Mallika Lala, Dinesh P De Alwis, Noboru Yamamoto   +2 more
exaly  

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of Oncology, 2019
O Hamid, Charlotte Robert, Adil Daud
exaly  

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Annals of Oncology, 2019
Biagio Ricciuti, L M Sholl, S Digumarthy   +2 more
exaly  

Pembrolizumab

Reactions Weekly, 2017
openaire   +1 more source

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Lancet, The, 2016
Roy S Herbst, Paul Baas, Dong-Wan Kim
exaly  

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
E P Winer, David W Cescon, R Nanda
exaly  

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Blood, 2019
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee   +2 more
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly